-
1
-
-
0025810796
-
Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67
-
COI: 1:CAS:528:DyaK3MXkt1Ohu7k%3D, PID: 2012175
-
Gerdes J, Li L, Schlueter C, Duchrow M, Wohlenberg C, Gerlach C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol. 1991;138:867–73.
-
(1991)
Am J Pathol
, vol.138
, pp. 867-873
-
-
Gerdes, J.1
Li, L.2
Schlueter, C.3
Duchrow, M.4
Wohlenberg, C.5
Gerlach, C.6
-
2
-
-
0020694123
-
Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation
-
COI: 1:STN:280:DyaL3s7lvF2nsA%3D%3D, PID: 6339421
-
Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13–20.
-
(1983)
Int J Cancer
, vol.31
, pp. 13-20
-
-
Gerdes, J.1
Schwab, U.2
Lemke, H.3
Stein, H.4
-
3
-
-
27244443082
-
Proliferation marker Ki-67 in early breast cancer
-
COI: 1:CAS:528:DC%2BD2MXhtFCrsbfK, PID: 16192605
-
Urruticoechea A, Smith IE, Dowsett M. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005;23:7212–20.
-
(2005)
J Clin Oncol
, vol.23
, pp. 7212-7220
-
-
Urruticoechea, A.1
Smith, I.E.2
Dowsett, M.3
-
4
-
-
34248595234
-
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients
-
PID: 17453008
-
de Azambuja E, Cardoso F, de Castro G, Jr, Colozza M, Mano, Durbecq V, et al. Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer. 2007;96:1504–13.
-
(2007)
Br J Cancer
, vol.96
, pp. 1504-1513
-
-
de Azambuja, E.1
Cardoso, F.2
de Castro, G.,3
Colozza, M.4
Mano, M.S.5
Durbecq, V.6
-
5
-
-
81555208345
-
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group
-
Dowsett M, Nielsen TO, A’Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group. J Natl Cancer Inst. 2011;103:1–9.
-
(2011)
J Natl Cancer Inst
, vol.103
, pp. 1-9
-
-
Dowsett, M.1
Nielsen, T.O.2
A’Hern, R.3
Bartlett, J.4
Coombes, R.C.5
Cuzick, J.6
-
6
-
-
75249083420
-
Ki67 in breast cancer: prognostic and predictive potential
-
COI: 1:CAS:528:DC%2BC3cXhtlGgtbc%3D, PID: 20152769
-
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11:174–83.
-
(2010)
Lancet Oncol
, vol.11
, pp. 174-183
-
-
Yerushalmi, R.1
Woods, R.2
Ravdin, P.M.3
Hayes, M.M.4
Gelmon, K.A.5
-
7
-
-
33749098961
-
Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer
-
COI: 1:STN:280:DC%2BD387kvFGjug%3D%3D, PID: 11881912
-
Billgren AM, Tani E, Liedberg A, Skoog L, Rutqvist LE. Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer. Breast Cancer Res Treat. 2002;71:161–70.
-
(2002)
Breast Cancer Res Treat
, vol.71
, pp. 161-170
-
-
Billgren, A.M.1
Tani, E.2
Liedberg, A.3
Skoog, L.4
Rutqvist, L.E.5
-
8
-
-
0034896073
-
Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer
-
COI: 1:STN:280:DC%2BD3Mzkslansg%3D%3D, PID: 11410511
-
Liu S, Edgerton SM, Moore DH 2nd, Thor AD. Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer. Clin Cancer Res. 2001;7:1716–23.
-
(2001)
Clin Cancer Res
, vol.7
, pp. 1716-1723
-
-
Liu, S.1
Edgerton, S.M.2
Moore, D.H.3
Thor, A.D.4
-
9
-
-
0030002609
-
Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis
-
COI: 1:STN:280:DyaK283gtFOhtg%3D%3D, PID: 8608982
-
Seshadri R, Leong AS, McCaul K, Firgaira FA, Setlur V, Horsfall DJ. Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis. Int J Cancer. 1996;69:135–41.
-
(1996)
Int J Cancer
, vol.69
, pp. 135-141
-
-
Seshadri, R.1
Leong, A.S.2
McCaul, K.3
Firgaira, F.A.4
Setlur, V.5
Horsfall, D.J.6
-
10
-
-
57149103724
-
Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole
-
PID: 18981464
-
Viale G, Giobbie-Hurder A, Regan MM, Coates AS, Mastropasqua MG, Dell’Orto P, et al. Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole. J Clin Oncol. 2008;26:5569–75.
-
(2008)
J Clin Oncol
, vol.26
, pp. 5569-5575
-
-
Viale, G.1
Giobbie-Hurder, A.2
Regan, M.M.3
Coates, A.S.4
Mastropasqua, M.G.5
Dell’Orto, P.6
-
11
-
-
69449090120
-
Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009
-
COI: 1:STN:280:DC%2BD1Mrjtlyhug%3D%3D, PID: 19535820
-
Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009;20:1319–29.
-
(2009)
Ann Oncol
, vol.20
, pp. 1319-1329
-
-
Goldhirsch, A.1
Ingle, J.N.2
Gelber, R.D.3
Coates, A.S.4
Thurlimann, B.5
Senn, H.J.6
-
12
-
-
79960980007
-
Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
-
COI: 1:STN:280:DC%2BC3Mjhs1ygug%3D%3D, PID: 21709140
-
Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22:1736–47.
-
(2011)
Ann Oncol
, vol.22
, pp. 1736-1747
-
-
Goldhirsch, A.1
Wood, W.C.2
Coates, A.S.3
Gelber, R.D.4
Thurlimann, B.5
Senn, H.J.6
-
13
-
-
36849069347
-
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer
-
COI: 1:CAS:528:DC%2BD2sXhsVKnsbzK, PID: 17954709
-
Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287–312.
-
(2007)
J Clin Oncol
, vol.25
, pp. 5287-5312
-
-
Harris, L.1
Fritsche, H.2
Mennel, R.3
Norton, L.4
Ravdin, P.5
Taube, S.6
-
14
-
-
66849140730
-
Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer
-
COI: 1:CAS:528:DC%2BD1MXmtlyit74%3D, PID: 19436038
-
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736–50.
-
(2009)
J Natl Cancer Inst
, vol.101
, pp. 736-750
-
-
Cheang, M.C.1
Chia, S.K.2
Voduc, D.3
Gao, D.4
Leung, S.5
Snider, J.6
-
15
-
-
27644579899
-
Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial
-
COI: 1:STN:280:DC%2BD2Mrns1ehtA%3D%3D, PID: 16254100
-
Jirstrom K, Ryden L, Anagnostaki L, Nordenskjold B, Stal O, Thorstenson S, et al. Pathology parameters and adjuvant tamoxifen response in a randomised premenopausal breast cancer trial. J Clin Pathol. 2005;58:1135–42.
-
(2005)
J Clin Pathol
, vol.58
, pp. 1135-1142
-
-
Jirstrom, K.1
Ryden, L.2
Anagnostaki, L.3
Nordenskjold, B.4
Stal, O.5
Thorstenson, S.6
-
16
-
-
0032135573
-
Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section
-
COI: 1:STN:280:DyaK1cvktF2iug%3D%3D, PID: 9769782
-
Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Watanabe T. Establishment of histological criteria for high-risk node-negative breast carcinoma for a multi-institutional randomized clinical trial of adjuvant therapy. Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) Pathology Section. Jpn J Clin Oncol. 1998;28:486–91.
-
(1998)
Jpn J Clin Oncol
, vol.28
, pp. 486-491
-
-
Tsuda, H.1
Akiyama, F.2
Kurosumi, M.3
Sakamoto, G.4
Watanabe, T.5
-
17
-
-
0034031038
-
Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol
-
COI: 1:CAS:528:DC%2BD3cXislGrsLg%3D, PID: 10804295
-
Tsuda H, Akiyama F, Kurosumi M, Sakamoto G, Yamashiro K, Oyama T, et al. Evaluation of the interobserver agreement in the number of mitotic figures of breast carcinoma as simulation of quality monitoring in the Japan National Surgical Adjuvant Study of Breast Cancer (NSAS-BC) protocol. Jpn J Cancer Res. 2000;91:451–7.
-
(2000)
Jpn J Cancer Res
, vol.91
, pp. 451-457
-
-
Tsuda, H.1
Akiyama, F.2
Kurosumi, M.3
Sakamoto, G.4
Yamashiro, K.5
Oyama, T.6
-
18
-
-
49249129393
-
Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy
-
PID: 18669459
-
Honma N, Horii R, Iwase T, Saji S, Younes M, Takubo K, et al. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy. J Clin Oncol. 2008;26:3727–34.
-
(2008)
J Clin Oncol
, vol.26
, pp. 3727-3734
-
-
Honma, N.1
Horii, R.2
Iwase, T.3
Saji, S.4
Younes, M.5
Takubo, K.6
-
19
-
-
0035087639
-
Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer
-
COI: 1:CAS:528:DC%2BD3MXjtVSgsb4%3D, PID: 11274641
-
Rudolph P, Alm P, Olsson H, Heidebrecht HJ, Ferno M, Baldetorp B, et al. Concurrent overexpression of p53 and c-erbB-2 correlates with accelerated cycling and concomitant poor prognosis in node-negative breast cancer. Hum Pathol. 2001;32:311–9.
-
(2001)
Hum Pathol
, vol.32
, pp. 311-319
-
-
Rudolph, P.1
Alm, P.2
Olsson, H.3
Heidebrecht, H.J.4
Ferno, M.5
Baldetorp, B.6
-
20
-
-
0036840908
-
Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial
-
PID: 12375261
-
Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller-Hermelink HK, Kreipe H. Inter-laboratory and inter-observer reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol. 2002;198:292–9.
-
(2002)
J Pathol
, vol.198
, pp. 292-299
-
-
Mengel, M.1
von Wasielewski, R.2
Wiese, B.3
Rudiger, T.4
Muller-Hermelink, H.K.5
Kreipe, H.6
-
21
-
-
0033015048
-
Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer
-
COI: 1:STN:280:DyaK1M7nvVKksA%3D%3D, PID: 10080587
-
Thor AD, Liu S, Moore DH 2nd, Edgerton SM. Comparison of mitotic index, in vitro bromodeoxyuridine labeling, and MIB-1 assays to quantitate proliferation in breast cancer. J Clin Oncol. 1999;17:470–7.
-
(1999)
J Clin Oncol
, vol.17
, pp. 470-477
-
-
Thor, A.D.1
Liu, S.2
Moore, D.H.3
Edgerton, S.M.4
-
22
-
-
0035914249
-
Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer
-
COI: 1:CAS:528:DC%2BD3MXoslamu74%3D, PID: 11710821
-
Bottini A, Berruti A, Bersiga A, Brizzi MP, Bruzzi P, Aguggini S, et al. Relationship between tumour shrinkage and reduction in Ki67 expression after primary chemotherapy in human breast cancer. Br J Cancer. 2001;85:1106–12.
-
(2001)
Br J Cancer
, vol.85
, pp. 1106-1112
-
-
Bottini, A.1
Berruti, A.2
Bersiga, A.3
Brizzi, M.P.4
Bruzzi, P.5
Aguggini, S.6
-
23
-
-
0032816621
-
Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases
-
COI: 1:STN:280:DyaK1MzpvFOmuw%3D%3D, PID: 10472780
-
Rudolph P, MacGrogan G, Bonichon F, Frahm SO, de Mascarel I, Trojani M, et al. Prognostic significance of Ki-67 and topoisomerase IIalpha expression in infiltrating ductal carcinoma of the breast. A multivariate analysis of 863 cases. Breast Cancer Res Treat. 1999;55:61–71.
-
(1999)
Breast Cancer Res Treat
, vol.55
, pp. 61-71
-
-
Rudolph, P.1
MacGrogan, G.2
Bonichon, F.3
Frahm, S.O.4
de Mascarel, I.5
Trojani, M.6
-
24
-
-
0032904256
-
Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications
-
COI: 1:CAS:528:DyaK1MXht1Cnu7w%3D, PID: 10365096
-
Rudolph P, Olsson H, Bonatz G, Ratjen V, Bolte H, Baldetorp B, et al. Correlation between p53, c-erbB-2, and topoisomerase II alpha expression, DNA ploidy, hormonal receptor status and proliferation in 356 node-negative breast carcinomas: prognostic implications. J Pathol. 1999;187:207–16.
-
(1999)
J Pathol
, vol.187
, pp. 207-216
-
-
Rudolph, P.1
Olsson, H.2
Bonatz, G.3
Ratjen, V.4
Bolte, H.5
Baldetorp, B.6
-
25
-
-
20244374922
-
Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker?
-
COI: 1:CAS:528:DC%2BD3sXisVKhuro%3D, PID: 12599241
-
Trihia H, Murray S, Price K, Gelber RD, Golouh R, Goldhirsch A, et al. Ki-67 expression in breast carcinoma: its association with grading systems, clinical parameters, and other prognostic factors—a surrogate marker? Cancer. 2003;97:1321–31.
-
(2003)
Cancer
, vol.97
, pp. 1321-1331
-
-
Trihia, H.1
Murray, S.2
Price, K.3
Gelber, R.D.4
Golouh, R.5
Goldhirsch, A.6
-
26
-
-
18244406327
-
Estrogen receptors and proliferation markers in primary and recurrent breast cancer
-
COI: 1:CAS:528:DC%2BD38XpsVal, PID: 11734621
-
Jensen EV, Cheng G, Palmieri C, Saji S, Makela S, Van Noorden S, et al. Estrogen receptors and proliferation markers in primary and recurrent breast cancer. Proc Natl Acad Sci USA. 2001;98:15197–202.
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 15197-15202
-
-
Jensen, E.V.1
Cheng, G.2
Palmieri, C.3
Saji, S.4
Makela, S.5
Van Noorden, S.6
-
27
-
-
9144226888
-
Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers
-
PID: 15477865
-
O’Neill PA, Davies MP, Shaaban AM, Innes H, Torevell A, Sibson DR, et al. Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in tamoxifen-treated post-menopausal breast cancers. Br J Cancer. 2004;91:1694–702.
-
(2004)
Br J Cancer
, vol.91
, pp. 1694-1702
-
-
O’Neill, P.A.1
Davies, M.P.2
Shaaban, A.M.3
Innes, H.4
Torevell, A.5
Sibson, D.R.6
-
28
-
-
33748305646
-
Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours
-
COI: 1:CAS:528:DC%2BD28XovVWitLs%3D, PID: 16880783
-
Skliris GP, Leygue E, Curtis-Snell L, Watson PH, Murphy LC. Expression of oestrogen receptor-beta in oestrogen receptor-alpha negative human breast tumours. Br J Cancer. 2006;95:616–26.
-
(2006)
Br J Cancer
, vol.95
, pp. 616-626
-
-
Skliris, G.P.1
Leygue, E.2
Curtis-Snell, L.3
Watson, P.H.4
Murphy, L.C.5
|